Site Search

The Innovative Medicines Initiative (IMI) welcomes the proposal to launch a new public-private partnership (PPP) for health under Horizon Europe, and hopes that the Innovative Health Initiative (IHI) will build on the successes and lessons learnt from IMI. Since the launch of the ...

The diagnostic projects launched by IMI in 2020 are making steady progress.

STOPFOP are trialling the cancer drug saracatinib, which has shown promise in stopping muscle and tissue from turning to bone in FOP patients.

COMBACTE-NET partner Da Volterra can move forward with phase 3 trial of an innovative product used to protect the microbiome of patients from antibiotic-induced disruption

From co-design to connecting the dots, paediatric cancer needs to be integrated along the healthcare continuum

COMBACTE-MAGNET has launched a new, freely-accessible online tool that allows healthcare professionals and the public to assess the risk of international travellers acquiring (and spreading) antimicrobial-resistant bacteria

ARDAT want to know more about the behaviour of gene and cell therapy treatments, delivered by viral vectors, once they’re inside the body

From genetic newborn screening to helping pharma create a unified, shared platform for treating thousands of rare diseases, IMI stands ready to help drive the science forward.

In January, we focussed on paediatric medicine.